ABL1 and dermatofibrosarcoma protuberans: Leukemia, Lymphoid (FDA-approved); Mastocytosis (FDA-approved); Leukemia, Myelogenous, Chronic, BCR-ABL Positive (FDA-approved); Dermatofibrosarcoma Protuberans (FDA-approved); Hypereosinophilic Syndrome (FDA-approved); Leukemia, Eosinophilic, Chronic (FDA-approved); Gastrointestinal Stromal Tumors (FDA-approved); Myeloproliferative Disorders (FDA-approved).